共 12 条
[1]
Bakris George, 2010, Am J Cardiol, V105, p21A, DOI 10.1016/j.amjcard.2009.10.010
[2]
Braunwald E, 2004, NEW ENGL J MED, V351, P2058
[4]
Fox KM, 2003, LANCET, V362, P782
[5]
Hoogwerf Byron J, 2010, Am J Cardiol, V105, p30A, DOI 10.1016/j.amjcard.2009.10.009
[6]
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)
[J].
EUROPEAN HEART JOURNAL,
2009, 30 (10)
:1203-1212
[9]
Influence of Coronary Risk Factors on Coronary Events in Japanese High-Risk Hypertensive Patients - Primary and Secondary Prevention of Ischemic Heart Disease in a Subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial
[J].
CIRCULATION JOURNAL,
2011, 75 (10)
:2411-2416